PEDIATRIC ONCOLOGY GROUP

儿科肿瘤学小组(POG)是一个多学科、多领域的 致力于寻找更好治疗方法的机构研究社区 治疗儿童癌症和白血病。麦吉尔大学，POG的创始人 成员，请求支持继续为POG的各个方面做出贡献 生物学、治疗性、流行病学和评估性临床癌症 未来5年的研究。我们将招收最大数量的 儿童白血病的多模式治疗研究， 淋巴瘤、实体瘤和脑瘤；以及非治疗性 癌症病因学、流行病学、生物学和远期效应的研究 心理治疗。我们正在招募一个卫星，渥太华大学，来 增加患者的收入，特别是脑瘤患者。我们 将遵守IRB道德要求和NCI要求 限制用药的毒性报告和控制。我们将继续 积极参与行政、教育和科学工作 POG的活动。 麦吉尔的调查人员将继续为POG科学做出贡献。急性 淋巴细胞性白血病(ALL)：怀特黑德博士研究了组织递送 抗白血病药物的两个前线所有方案(ALinC 14和15)。 他将检验这一假设，即甲氨蝶呤在人体内的代谢程度 诊断时的淋巴母细胞影响ALinC患者的ALL无事件生存率 15.新的药物和药理学：伯恩斯坦和怀特黑德博士 协调异磷酰胺和VP-16在白血病(I期)中的研究。 他们将协调法扎拉宾在白血病和白血病中的两个I期研究 在实体瘤中。神经肿瘤学：弗里曼博士将继续研究 脑干胶质瘤的超分割放射治疗。巴鲁切尔博士 将在脑瘤中进行Acivicin的I期研究。这所大学 渥太华大学将首先专注于脑瘤的研究。骨 骨髓移植(BMT)：政府将资助4个骨髓移植床位 允许科赫博士招募更多的患者参加POG BMT方案。艾滋病病毒 感染：Baruchel博士发起了一个特设委员会，并是该委员会的成员 目的：研究POG中HIV相关淋巴瘤的发生。神经母细胞瘤：伯恩斯坦医生 成立了一个协作小组；包括POG，以确定是否 神经母细胞瘤可通过筛查魁北克新生儿早期发现 尿儿茶酚胺升高。魁北克所有患有神经母细胞瘤的儿童， 临床诊断或临床前诊断，将在POG中登记 协议。

The Pediatric Oncology Group (POG) is a multi-disciplinary, multi- institutional research community dedicated to finding better treatments for childhood cancer and leukemia. McGill University, a POG founding member, requests support to continue to contribute to all aspects of POG biologic, therapeutic, epidemiologic and evaluative clinical cancer research for the next 5 years. We will enroll the maximum number of patients into multi-modality therapeutic studies of childhood leukemias, lymphomas, solid tumors, and brain tumors; and into non-therapeutic studies of cancer etiology, epidemiology, biology, and late effects of therapy. We are recruiting a satellite, the University of Ottawa, to increase patient accrual, particularly patients with brain tumors. We will comply with IRB ethical requirements and NCI requirements for toxicity reporting and control of restricted drugs. We will continue to participate actively in the administrative, educational and scientific activities of the POG. McGill investigators will continue to contribute to POG science. Acute lymphoblastic leukemia (ALL): Dr. Whitehead has studied tissue delivery of anti-leukemic drugs in two frontline ALL protocols (ALinC 14 and 15). He will test the hypothesis that extent of metabolism of methotrexate in lymphoblasts at diagnosis influences event-free survival in ALL in ALinC 15. New agents and pharmacology: Drs. Bernstein and Whitehead are coordinating a study of Ifosphamide and VP-16 in leukemia (phase I). They will coordinate two phase I studies of Fazarabine in leukemia and in solid tumors. Neuro-oncology: Dr. Freeman will continue to study hyperfractionated radiation therapy in brain stem gliomas. Dr. Baruchel will conduct a phase I study of Acivicin in brain tumors. The University of Ottawa will concentrate initially on the study of brain tumors. Bone marrow transplantation (BMT): Government funding for 4 BMT beds will allow Dr. Koch to enroll many more patients on POG BMT protocols. HIV infection: Dr. Baruchel initiated and is a member of an ad hoc committee to study HIV-associated lymphoma in POG. Neuroblastoma: Dr. Bernstein formed a collaborative group; including POG, to determine whether neuroblastoma can be detected early by screening Quebec newborns for elevated urinary catecholamines. All Quebec children with neuroblastoma, diagnosed clinically or pre-clinically, will be enrolled on POG protocols.